Hear: The way forward for AbbVieGan, the dogma of amyloid, & some questionable biotech advertising and marketing

Can Botox make Massive Pharma engaging? What qualifies as a “cabal”? And can the CRISPR patent battle outlive us all?

We talk about all that and extra on the most recent episode of “The Readout LOUD,” STAT’s biotech podcast. First, we choose aside the proposed merger of AbbVie and Allergan, a pharmaceutical marriage of comfort with huge implications for the drug enterprise. Second, STAT’s Sharon Begley joins us to debate her story on how scientific dogma thwarted new concepts in Alzheimer’s illness analysis. Then we dig right into a curious little bit of biotech advertising and marketing that left some key details unspoken. Lastly, we embark on a lightning spherical, that includes CRISPR patents, Democratic candidates, and a pugilistic federal company.

For extra on what we cowl, right here’s the story on Allergan’s CEO; right here’s a deep dive into amyloid; right here’s the information on that stem cell trial; right here’s the most recent on CRISPR patents; and right here’s a recap of the primary Democratic presidential debate.


We’ll be again subsequent Thursday night — and each Thursday night — so make sure you enroll on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And you probably have any suggestions for us — subjects to cowl, friends to ask, vocal tics to stop — you possibly can e mail readoutloud@statnews.com.

Desirous about sponsoring a future episode of “The Readout LOUD”? E mail us at advertising and marketing@statnews.com.